The deal size was increased to $225M in common stock from $200M in common stock. Morgan Stanley, JPMorgan, TD Cowen and Stifel acted as joint book running managers for the offering.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Announces Pricing of $225 Million Public Offering
- Kymera Therapeutics Announces Proposed Public Offering
- Kymera Therapeutics price target raised to $45 from $34 at Morgan Stanley
- Kymera Therapeutics price target raised to $38 from $30 at Wells Fargo
- Kymera Therapeutics price target raised to $60 from $46 at H.C. Wainwright